Collection of Blood Products for Use in the Development and Validation of Point-of-Care In Vitro Diagnostic Liver Function Test Devices
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Liver Diseases
- Sponsor
- Group K Diagnostics Inc.
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Regression analysis of bilirubin test results
- Last Updated
- 3 years ago
Overview
Brief Summary
This is an observational study exploring the performance of a novel point-of-care diagnostic testing platform designed to quantitate the presence of liver function biomarkers such as bilirubin. Blood samples will be collected from participants to further development and validation of the testing platform to support FDA review. The diagnostic device is intended to provide rapid in-office test results using a finger stick of blood, a reaction test device, and a smartphone app.
Detailed Description
The nature of outpatient diagnostics delays diagnosis and proper treatment due to the need to travel to a sample collection site that is designed for volume testing adding the individual's sample to the testing que. The physical and temporal separation of diagnostic testing from medical office or virtual care visits delays physician decision-making until results are available. Many patients even skip the recommended testing due to time and financial costs. Many acute and chronic conditions result in disruption of normal liver function. Common prescription and over-the-counter medications also affect liver function when taken over extended periods or at elevated doses. Having multiple rapid, easy-to-use diagnostic tests on a single platform could improve condition diagnosis and medication monitoring by ensuring current test results are available every time and anywhere they could be useful for immediate medical decision-making. This study will provide fresh blood samples for further development and validation of a novel point-of-care diagnostic testing platform. Tests for liver function biomarkers such as bilirubin, ALT (alanine transaminase), and AST (aspartate aminotransferase) will be characterized and validated using fresh whole blood, freshly prepared serum, and frozen serum. Enrolled participants will have a standard venous and a standard finger stick blood collection. Enrolled participants can return once weekly for blood draws or can chose to have only a single study visit. The study will continue until sufficient data has been generated to support review of the tests by the FDA.
Investigators
Laura M Ferguson, PhD
Chief Scientific Officer
Group K Diagnostics Inc.
Eligibility Criteria
Inclusion Criteria
- •18 years of age and older
- •Able to read and understand an informed consent form written in English
Exclusion Criteria
- •Pregnancy
- •Participated in the present study within the last 6 days
- •Subject is subjectively unwell at the time of enrollment visit
- •Subject previously participated and has asked to be withdrawn from the study
Outcomes
Primary Outcomes
Regression analysis of bilirubin test results
Time Frame: 6 months
Regression and other statistical analyses will be applied to bilirubin tests results to evaluate quantitation linearity, precision, and accuracy relative to a predicate device.
Secondary Outcomes
- Sensitivity of image analysis to changes in concentration of test analyte(9 months)